How to Register a Foreign Drug in China: 2026 Guide

Last Updated: July 2026 | Reading Time: 14 minutes

Introduction

China is the world’s second-largest pharmaceutical market, with projected spending exceeding USD 200 billion by 2028. For foreign pharmaceutical companies, gaining access to this market through drug registration is both a massive opportunity and a formidable regulatory challenge. The National Medical Products Administration (NMPA, formerly CFDA) has undertaken sweeping reforms since 2017 to accelerate drug approvals, align with international standards, and encourage innovation — yet the process remains complex, time-consuming, and resource-intensive.

This 2026 guide provides a comprehensive, step-by-step overview of the foreign drug registration process in China. It covers the regulatory framework, dossier preparation, clinical trial requirements, application pathways, timelines, costs, and strategic considerations for bringing a foreign-developed drug to the Chinese market.

The Regulatory Framework in 2026

China’s drug regulatory environment has been transformed by a series of landmark reforms:

• 2015-2017 reforms: The “Opinions on Reform of the Review and Approval System for Drugs and Medical Devices” (Document 44) and subsequent implementing regulations laid the groundwork for accelerated approvals, priority review, and acceptance of overseas clinical trial data.
• 2019 Drug Administration Law (DAL): The comprehensively revised DAL took effect December 1, 2019, establishing the legal framework for the current regulatory system, including enhanced pharmacovigilance, marketing authorization holder (MAH) system, and expedited pathways.
• 2020 Implementing Regulations: Supporting regulations under the DAL provided detailed implementing rules for registration, manufacturing, distribution, and pharmacovigilance.
• 2023-2024 NMPA Guideline Updates: The NMPA has issued a series of technical guidelines aligning China’s requirements with ICH (International Council for Harmonisation) guidelines, including comprehensive guidelines on quality, safety, and efficacy data.
• 2024-2026 Accelerated Pathways: The NMPA’s Center for Drug Evaluation (CDE) has expanded breakthrough therapy designation, priority review, and conditional approval pathways, significantly reducing approval timelines for innovative drugs.

As of 2026, China has fully adopted nearly all ICH guidelines (Quality, Safety, Efficacy, and Multidisciplinary guidelines), making the technical data requirements substantially similar to those of the US FDA and EMA. This alignment has significantly reduced the burden for foreign sponsors whose drugs have already been approved in ICH jurisdictions.

Overview of the Registration Process

The foreign drug registration process in China can be divided into five major phases:

Total typical timeline for a complete registration: 2.5 to 5 years from pre-submission to market approval, depending on the drug type, clinical trial requirements, and approval pathway.

Phase 1: Pre-Submission Strategy

Regulatory Classification

The first step is determining the drug’s regulatory classification under China’s system:

• Class 1 (创新药 / Innovative Drug): New molecular entities not previously marketed anywhere in the world. Eligible for breakthrough therapy designation and priority review.
• Class 2.2 (改良型新药 / Modified New Drug): Drugs that are structural modifications of known drugs with improved clinical value.
• Class 5.1 (境外原研药品 / Originator Drug): Drugs already approved outside China and being imported into China for the first time. This is the most common classification for foreign drugs.
• Class 5.2 (境外非原研药品 / Non-Originator Drug): Generic versions of drugs already approved abroad.

Gap Analysis

Conduct a comprehensive gap analysis comparing your existing dossier (originally prepared for FDA/EMA submission) against China-specific requirements:

• Quality (CMC): China may require additional stability data under Chinese Pharmacopoeia (ChP) conditions, specific impurity limits per ChP monographs, and China-specific elemental impurity testing. Note that while ICH Q1 stability conditions (25°C/60%RH or 30°C/65%RH) are generally accepted, long-term testing under Chinese conditions (30°C/65%RH as outlined in ChP 9001) may be recommended.
• Non-clinical safety: China generally accepts ICH-aligned non-clinical data. However, for certain drug classes — particularly traditional Chinese medicine (TCM) combinations and biological products — additional non-clinical studies may be required.
• Clinical efficacy: The most significant gap is often clinical data. China has historically required local clinical trials for registration, though reforms have expanded acceptance of overseas data under certain conditions.

Pre-IND / Pre-NDA Meeting

Request a pre-submission communication meeting (Pre-IND meeting for clinical trial applications, or Pre-NDA meeting for marketing applications) with the CDE. These meetings are intended to:

• Confirm the regulatory classification and applicable pathway
• Discuss clinical trial requirements and the acceptability of overseas clinical data
• Clarify CMC requirements specific to the Chinese market
• Identify potential issues before formal submission
• Seek CDE guidance on the overall development and registration strategy

Phase 2: Clinical Trial Application (CTA/IND)

When Are Local Clinical Trials Required?

One of the most consequential questions is whether your drug requires clinical trials conducted in China. The regulatory framework has evolved significantly:

• Innovative drugs (Class 1): Almost always require at least a Phase I/II China-based clinical trial to establish PK/PD data and safety profiles in the Chinese population, followed by a Phase III bridging or global trial that includes Chinese sites.
• Drugs already approved in ICH regions (Class 5.1): May qualify for reduced clinical trial requirements. Under the 2018 CDE guidelines on “Acceptance of Overseas Clinical Trial Data,” if the drug is approved in the US, EU, or Japan and meets certain criteria (such as no significant ethnic sensitivity, adequate safety database including Asian data), you may be able to submit a marketing application with limited or no local clinical trial data.
• Ethnic sensitivity analysis: This is the key determinant. Drugs with high ethnic sensitivity — those with narrow therapeutic windows, high PK variability, or differences in metabolism correlates — may require bridging PK studies and/or local Phase III trials. Drugs with low ethnic sensitivity (e.g., most biologics, drugs with wide therapeutic indices) may qualify for abbreviated clinical pathways.

The IND/CTA Submission

The clinical trial application (also known as Import Drug Clinical Trial Approval) is submitted to CDE through the NMPA’s online registration platform. The dossier should follow the Common Technical Document (CTD) format and include:

• Module 1: Administrative information and prescribing information
• Module 2: Quality overall summary, non-clinical overview, clinical overview
• Module 3: Quality (CMC) data
• Module 4: Non-clinical study reports
• Module 5: Clinical study reports
• A detailed clinical trial protocol for the proposed China-based study
• Investigator’s brochure and informed consent forms in Chinese

Under the 2024-2026 reforms, the CDE has implemented a “silence is consent” system for IND applications: if CDE does not raise objections within 60 working days, the clinical trial is deemed approved and may proceed. This has dramatically reduced CTA review timelines from the previous 12-month average to approximately 3-4 months.

Ethics Approval

Concurrent with the CDE submission, the sponsor must obtain ethics committee approval from the hospital(s) where the clinical trial will be conducted. Major hospitals in Beijing, Shanghai, Guangzhou, and other leading medical centers have well-established ethics committees experienced in international clinical trials. Ethics approval typically takes 1-3 months.

Phase 3: Marketing Authorization (NDA) Application

Dossier Preparation

The New Drug Application (NDA) dossier is submitted to CDE in CTD format. China’s requirements are now closely aligned with ICH CTD, though certain China-specific elements remain:

• Executive summary: A comprehensive Chinese-language summary of the entire dossier
• Quality module: Full CMC data, including ChP-compliant specifications, comparative dissolution profiles (for solid oral dosage forms), and China-market specific packaging/ labeling
• Non-clinical module: Full non-clinical study reports. Accepts ICH-aligned studies
• Clinical module: Full clinical study reports, including China-specific clinical data if required
• Labeling and prescribing information: Chinese-language package insert (说明书) following the CDE-specified format, including indication(s), dosage and administration, contraindications, precautions, adverse reactions, drug interactions, and special population considerations

Review Pathways

Phase 4: Inspection and Testing

GMP Inspection

As part of the NDA review, the NMPA’s Center for Food and Drug Inspection (CFDI) will conduct a GMP compliance inspection of the overseas manufacturing site(s). This is one of the most practically challenging aspects of foreign drug registration:

• Inspection standards: China has adopted ICH Q7 (GMP for Active Pharmaceutical Ingredients) and has its own “Good Manufacturing Practice for Pharmaceutical Products” inspection standards, which are broadly aligned with but not identical to EU and US GMP standards.
• Inspection timeline: Typically 3-5 days per site, scheduled with approximately 4-8 weeks’ notice.
• Language: Inspections are conducted in Mandarin Chinese with interpreters provided by the manufacturer. Technical documents should be available in Chinese or bilingual format.
• Deficiencies: Common findings include issues with data integrity, quality system documentation, Chinese-language labeling compliance, and supply chain traceability. A major deficiency can delay approval by 6-12 months.
• Remote inspection: Since the COVID-19 pandemic, CFDI has developed remote inspection capabilities for overseas facilities. As of 2026, a hybrid approach is used — remote document review followed by on-site inspection where the CFDI deems necessary.

Sample Testing

The NMPA’s drug testing institutes (primarily the China National Institute for Food and Drug Control, NIFDC) will test samples of the drug product from the commercial batch for compliance with registered specifications. Testing typically takes 1-3 months and covers identity, purity, potency, dissolution, and other quality attributes.

Phase 5: Post-Approval Compliance

Marketing Authorization Holder (MAH) Obligations

Under the 2019 Drug Administration Law, all drug marketing authorization holders — including foreign applicants — have significant ongoing obligations:

• Pharmacovigilance (PV): Establish a China-based PV system with a qualified PV responsible person, maintain a Chinese adverse event reporting database, submit periodic safety update reports (PSURs) to CDE, and comply with serious adverse event reporting timelines (15 days for serious, 7 days for fatal).
• Quality management: Maintain a China-compliant pharmaceutical quality system, including batch release procedures, stability monitoring, and complaint handling.
• Post-approval changes: Any changes to the manufacturing process, specifications, labeling, or manufacturing site require CDE notification or approval, depending on the significance of the change (Major, Moderate, or Minor under the 2021 Post-Approval Change Management Guidelines).
• License renewal: Drug registration certificates are valid for 5 years and must be renewed before expiry.
• Annual reporting: Submit annual reports to CDE covering manufacturing changes, distribution data, PV data, and quality metrics.

Foreign MAH Requirements

Foreign marketing authorization holders must designate a China-based legal representative (代理人) who is responsible for:

• Registering the drug and holding the registration certificate
• Coordinating with CDE and local authorities
• Managing pharmacovigilance and adverse event reporting in China
• Facilitating inspections and testing
• Holding legal liability for the product in China
• Acting as the primary point of contact for all regulatory communications

The designated agent is typically a wholly foreign-owned entity (WFOE) established in China by the foreign sponsor or a licensed local pharmaceutical company acting under contract.

Strategic Considerations for Foreign Drug Registration

1. Early CDE Engagement

Engage with CDE early in the development process, not just before submission. CDE’s Pre-IND consultation and scientific advice mechanisms allow sponsors to get guidance on study design, data requirements, and approval pathways years before the NDA submission. Early engagement is particularly valuable for novel therapeutic modalities (cell and gene therapies, mRNA therapeutics, antibody-drug conjugates) where China-specific guidance may be evolving.

2. Global Development Strategy

For drugs in early development, consider a “China-inclusive” global development strategy from the start:

• Include Chinese clinical trial sites in global Phase III trials
• Generate Asian/ethnic subgroup data within global trials
• Conduct PK bridging studies early to address ethnic sensitivity questions
• Align manufacturing with Chinese GMP requirements from the initial process validation
• Prepare Chinese-language labeling and prescribing information in parallel with English-language versions

3. Market Exclusivity and Data Protection

China’s regulatory data protection regime provides limited but meaningful exclusivity:

• 6-year data exclusivity: For innovative drugs (Class 1), China provides 6 years of regulatory data protection from the date of marketing approval, during which generic applicants cannot rely on the originator’s undisclosed clinical trial data.
• Patent linkage: China’s patent linkage system (implemented in 2021) allows originator companies to challenge generic applicants during the NDA review process. The patent dispute resolution window extends up to 9 months.
• Pediatric exclusivity: Additional data protection may be available for pediatric indications studied in China.

4. Pricing and Reimbursement

Registration approval does not guarantee market access. Foreign drugs must also navigate China’s pricing and reimbursement system:

• National Reimbursement Drug List (NRDL): Annual negotiations for inclusion on the NRDL, which determines which drugs are reimbursed through China’s public health insurance system. NRDL inclusion is increasingly essential for commercial success but typically requires significant price concessions (30-70% discounts from international reference prices).
• Volume-based procurement (VBP): For off-patent and generic drugs, the centralized VBP system drives prices down through competitive bidding.
• Hospital formulary listing: Individual hospital formulary committees must approve drugs for use, a process that can add 6-18 months after NMPA approval.
• Provincial drug procurement platforms: Drugs must be listed on provincial procurement platforms before they can be purchased and prescribed.

Common Pitfalls and How to Avoid Them

1. Inadequate CMC preparation: The most common cause of review delays is quality data that does not fully meet ChP or CDE expectations. Engage a qualified Chinese CMC consultant early.
2. Underestimating ethnic sensitivity issues: A drug that requires China-only clinical trials can add 2-3 years to the timeline. Conduct ethnic sensitivity analysis early and seek CDE guidance on clinical trial requirements before committing to the development plan.
3. Poor translation quality: CDE reviewers work in Chinese. Poor translation of dossiers, labeling, and clinical data creates reviewer frustration and delays. Invest in professional pharmaceutical translation services.
4. Inadequate PV system: China’s PV requirements are now rigorous and actively enforced. Non-compliance can result in warning letters, fines, and even license suspension.
5. Neglecting post-approval changes: Many companies assume the process is over after approval. Changes in manufacturing, labeling, or specifications that are not properly filed can lead to regulatory action.
6. Choosing the wrong Chinese partner: Your regulatory agent, CRO, and commercialization partners are critical. Conduct thorough due diligence and consider companies with specific experience in your therapeutic area.

Conclusion

Registering a foreign drug in China is a complex, multi-year undertaking that requires strategic planning, regulatory expertise, and sustained commitment. However, the reforms of the past decade have made the process more transparent, predictable, and aligned with international standards than ever before. China’s pharmaceutical market offers enormous rewards for companies willing to navigate its regulatory system effectively.

The keys to success in 2026 are: engage CDE early, invest in a thorough gap analysis and regulatory strategy, prepare a comprehensive dossier that addresses China-specific requirements, build a robust Chinese pharmacovigilance system, and — above all — approach the process with patience and a long-term perspective.

Foreign pharmaceutical companies that invest in understanding and respecting China’s regulatory framework, rather than seeking shortcuts, will find a market that rewards quality, innovation, and commitment to the health of Chinese patients.